An Act amending the act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, in casualty insurance, providing for coverage for biomarker testing.

This bill requires private health insurers and state-managed health plans to cover biomarker testing when it is used to diagnose, treat, or monitor a specific disease or condition. The legislation defines biomarker testing as the analysis of tissue, blood, or other biological samples to identify indicators of biological processes, while explicitly excluding coverage for general screening purposes. Coverage for these tests must follow the same rules as other medical services, including standard cost-sharing and medical necessity reviews, and the changes will take effect 180 days after the bill is signed.